Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

被引:133
作者
Guan, R
Tapang, P
Leverson, JD
Albert, D
Giranda, VL
Luo, Y
机构
[1] Abbott Labs, Canc Res, Dept R47S, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Canc Res, Dept R47J, Abbott Pk, IL 60064 USA
关键词
D O I
10.1158/0008-5472.CAN-04-2131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polo-like kinase 1 (Plk1) is required for multiple stages of mitosis and is up-regulated in many human malignancies. We depleted Plk1 expression using small interfering RNA (siRNA) and showed defects in bipolar spindle formation and cytokinesis, growth inhibition, and apoptosis induction in human cancer cell lines. To our surprise, depletion of P1k1 in normal human cells did not result in obvious cell cycle defects, and did not induce significant inhibition of cell growth for at least two cell cycles. In addition, P1k1 siRNA inhibited colony formation in soft agar and tumorigenesis in a HT1080 xenograft model in a dose-dependent manner. Analysis with isogenic pairs of cell lines, differing in p53 status, revealed that P1k1 depletion preferentially induced mitotic arrest, aneuploidy, and reduced cell survival in the p53-defective cell lines. No obvious defects were observed in most p53 wild-type cells during the first few cell cycles. In addition, long-term survival studies revealed that p53 facilitates survival upon P1k1 depletion. Therefore, short-term inhibition of P1k1 can kill tumor cells while allowing normal cells to survive. These data validate the episodic inhibition of P1k1 as a very useful approach for cancer treatment.
引用
收藏
页码:2698 / 2704
页数:7
相关论文
共 43 条
  • [1] Abrieu A, 1998, J CELL SCI, V111, P1751
  • [2] Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615
  • [3] ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase
    Deming, PB
    Flores, KG
    Downes, CS
    Paules, RS
    Kaufmann, WK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) : 36832 - 36838
  • [4] Increased human polo-like kinase-1 expression in gliomas
    Dietzmann, K
    Kirches, E
    von Bossanyi, P
    Jachau, K
    Mawrin, C
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (01) : 1 - 11
  • [5] Polo-like kinases: a team that plays throughout mitosis
    Glover, DM
    Hagan, IM
    Tavares, AAM
    [J]. GENES & DEVELOPMENT, 1998, 12 (24) : 3777 - 3787
  • [6] GOLSTEYN RM, 1994, J CELL SCI, V107, P1509
  • [7] INDUCTION AND DOWN-REGULATION OF PLK, A HUMAN SERINE/THREONINE KINASE EXPRESSED IN PROLIFERATING CELLS AND TUMORS
    HOLTRICH, U
    WOLF, G
    BRAUNINGER, A
    KARN, T
    BOHME, B
    RUBSAMENWAIGMANN, H
    STREBHARDT, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (05) : 1736 - 1740
  • [8] Knecht R, 1999, CANCER RES, V59, P2794
  • [9] Knecht R, 2000, INT J CANCER, V89, P535
  • [10] Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
    Kneisel, L
    Strebhardt, K
    Bernd, A
    Wolter, M
    Binder, A
    Kaufmann, R
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2002, 29 (06) : 354 - 358